Recro Pharma Stock News

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

Recro Pharma, Inc. (NASDAQ:REPH) was the recipient of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 823,800 shares, a growth of 22.5% from the October 31st total of 672,500 shares. Based on an average daily trading volume, of 325,300 shares, the short-interest ratio []

Recro Pharma, Inc. (NASDAQ:REPH) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 823,800 shares, a growth of 22.5% from the October 31st total of 672,500 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily []

Zacks Investment Research upgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a buy rating in a research report released on Thursday, Zacks.com reports. They currently have $1.75 target price on the specialty pharmaceutical companys stock. According to Zacks, Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics []

AQR Capital Management LLC lessened its holdings in shares of Recro Pharma, Inc. (NASDAQ:REPH) by 42.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,996 shares of the specialty pharmaceutical company’s stock after selling 14,692 shares during the […]

Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript

Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).

Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego

Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.

Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth

Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms

Recro Pharma, Inc. (REPH) CEO David Enloe on Q2 2021 Results - Earnings Call Transcript

Shares of Recro Pharma (NASDAQ:REPH) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 112.00% over the past year to $0.03, which beat th